Table 2.
Selected ongoing trials—Early/locally advanced cervical cancer.
| Trial Identifier | Study Phase | Study Population | Intervention |
|---|---|---|---|
| NCT04221945 | III | FIGO 2014 IB2-IIB (node positive), FIGO 2014 II-IVA | CRT vs. CRT + concurrent and adjuvant pembrolizumab |
| NCT03830866 | III | FIGO (2009) Stages IB2 to IIB node positive or FIGO (2009) IIIA-IVA any nodal status | CRT vs. CRT + durvalumab then durvalumab maintenance (2 years) |
| NCT02635360 | II | - | CRT + concurrent Pembrolizumab vs. CRT adjuvant pembrolizumab |
| NCT03527264 | II | FIGO 1B-IVA | 1A: CRT + concurrent Nivolumab (whole pelvic RT) 1B: CRT + concurrent Nivolumab (extended field RT) 2: CRT + Nivolumab maintenance (total 2 years) 3: CRT + concurrent Nivolumab then maintenance Nivolumab (total 2 years) |
| NCT03612791 | II | FIGO IB2-IVB (limited to PA nodes) | CRT vs. CRT + concurrent atezolizumab (atezolizumab total 20 cycles) |
| NCT03833479 | II | FIGO IB2/IIA2/IIB (positive pelvic LN) FIGO IIIA/IIIB/IVA | CRT + consolidation TSR-042 (2 years) |
| NCT04238988 | II | FIGO IB2-IIB | Neoadjuvant carboplatin + paclitaxel + pembrolizumab → surgery → Adjuvant carboplatin-paclitaxel-pembrolizumab (high-risk patients) |
| NCT01711515 | I | FIGO (2014) IB2/IIA (+para-aortic LN), IIB/IIIB/IVA | CRT + adjuvant Ipilimumab |
| NCT04256213 | Pilot | FIGO IB3-IVA | Ipilimumab + Nivolumab + CRT |
CRT, chemoradiotherapy; LN, lymph node; PA, para-aortic; RT, radiotherapy.